While current treatment and liver transplantation strategies are reasonably effective for patients with early stage liver cancer, once the disease has advanced it becomes much harder to treat. Checkpoint immunotherapy has provided relief for some patients with advanced liver cancer, but the majority of patients still either don’t respond to the treatment or else develop resistance after initially responding. To address this, Dr. Guangchuan Wang is using a novel gene-editing approach to discover new factors that are responsible for resistance to immunotherapy. Identifying and validating the contribution of these factors will provide insights that could be used to improve immunotherapy approaches for liver cancer by helping doctors determine treatments might work best for which patients as well as highlighting novel targets for which future therapies could be developed.
Yale University | Liver Cancer | 2017 | Sidi Chen, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
In February 2017, Oswald became one of the first patients to receive pembrolizumab (Keytruda®) as first-line therapy for non-small cell lung cancer.
Dr. Kunle Odunsi discusses genomic testing, new treatments, and promising clinical trials in immunotherapy for ovarian cancer.